Research programme: anti-latent virus therapy - Gemin X
Alternative Names: Anti-latent virus therapy research programme - Gemin XLatest Information Update: 27 May 2011
At a glance
- Originator Gemin X Biotechnologies
- Class Oncolytic viruses
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Epstein-Barr virus infections; Herpesvirus infections
Most Recent Events
- 22 Mar 2004 This programme is still in active development
- 18 Oct 2001 Preclinical development for Epstein-Barr virus infections in Canada (Unknown route)
- 18 Oct 2001 Preclinical development for Herpesvirus infections in Canada (Unknown route)